Logo Image
News|Articles|May 19, 2026

TrumpRx Expands Generic Drug Offerings With Mark Cuban Partnership, Amazon Pharmacy Support

Fact checked by: Christina Mattina
Listen
0:00 / 0:00

Key Takeaways

  • TrumpRx now prioritizes generics that comprise ~90% of US prescriptions, shifting from a brand-heavy list toward medications more likely to affect broad population-level out-of-pocket spending.
  • Integration with Cost Plus Drugs, Amazon Pharmacy, and GoodRx positions TrumpRx as an aggregator that routes consumers to alternative cash-price channels rather than dispensing directly.
SHOW MORE

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

President Donald J. Trump announced on Monday that the administration’s online prescription pricing platform, TrumpRx, is expanding to include more than 600 generic medications in a move aimed at lowering out-of-pocket drug costs for Americans.1

The announcement came during a White House event featuring several high-profile partners, including Mark Cuban, whose Mark Cuban Cost Plus Drug Company will now integrate with the TrumpRx platform. Additional partners include Amazon Pharmacy and GoodRx.

TrumpRx, launched earlier this year, functions as a government-run price comparison website rather than a direct pharmacy. The platform allows users to search medications and compare cash prices across pharmacies and online providers.2 The newly added generic medications include commonly prescribed blood pressure drugs, antibiotics, and statins, many priced under $5.1

The partnership marks a notable moment of bipartisan alignment between Trump and Cuban, who publicly opposed Trump during the 2024 presidential campaign and endorsed former Vice President Kamala Harris. Despite their political differences, Cuban praised the administration’s efforts to address prescription affordability.

The expansion significantly broadens TrumpRx’s inventory. Prior to Monday’s announcement, the site listed only 74 medications, most of them brand-name products, including obesity drugs and fertility treatments. The addition of more than 600 generics reflects a shift toward medications that represent the majority of prescriptions filled in the US. Approximately 90% of all US prescriptions are for generic drugs.

Some product pages on TrumpRx now include interactive neighborhood maps that allow consumers to compare pricing between nearby pharmacies. In some cases, users searching for generic medications will be redirected to the Mark Cuban Cost Plus Drug Company, which has gained attention for offering lower-cost generic medications through a transparent pricing model.

Founded in 2022, Cost Plus Drugs now offers more than 2300 medications and applies a fixed 15% markup before mailing prescriptions directly to patients. The company has carved out a niche among consumers facing high out-of-pocket costs despite having insurance coverage.

Trump’s latest prescription drug initiative comes amid broader concerns over affordability as Americans continue to grapple with rising living costs. The administration has increasingly emphasized drug pricing reform as a key economic message, particularly as global instability and the ongoing war in Iran contribute to inflationary pressures.

In recent months, the administration has also negotiated agreements with pharmaceutical manufacturers to avoid threatened tariffs in exchange for select pricing concessions and participation in TrumpRx.

Still, analysts note that the direct impact on consumers may remain limited for now. Although some Medicare beneficiaries are expected to benefit from lower monthly costs for certain obesity medications, broader prescription savings for most Americans have yet to materialize.

Previously, in an interview with The American Journal of Managed Care® (AJMC®), Robert Andrews, former US representative for New Jersey and CEO of the Health Transformation Alliance, noted that while TrumpRx could improve access to lower-cost generic medications, the platform’s overall impact on prescription affordability may remain limited—particularly for high-cost specialty therapies.3 

“It signals that the policy is headed in the right direction, because anything that would provide relief to people from very high [prescription drug] prices is welcome,” said Andrews. “It also signals, though, that this is an effort that's heavy on symbolism but relatively light on real impact.”

The administration says the expansion of TrumpRx is part of a larger effort to increase transparency and competition in the prescription drug market while giving consumers more tools to compare prices and reduce out-of-pocket spending.1

References

1. Robbins R. TrumpRx adds generic drugs, with Mark Cuban, GoodRx and Amazon. New York Times. May 18, 2026. Accessed May 19, 2026. https://www.nytimes.com/2026/05/18/business/trumprx-generic-drugs-mark-cuban.html

2. Joszt L. White House, Pfizer reach agreement on drug discounts; Trump announces TrumpRx. AJMC. September 30, 2025. Accessed May 19, 2026. https://www.ajmc.com/view/white-house-pfizer-reach-agreement-on-drug-discounts-trump-announces-trumprx

3. Steinzor P, Andrews R. TrumpRx signals limited impact, but a symbolic shift in drug pricing policy: Robert Andrews. AJMC. October 8, 2025. Accessed May 19, 2026. https://www.ajmc.com/view/trumprx-signals-limited-impact-but-a-symbolic-shift-in-drug-pricing-policy-robert-andrews

Related Content